Objective To investigate the effect of vedolizumab combined with compound glutamine enteric-coated capsules in the treatment of ulcerative colitis(UC).Methods A total of 102 UC patients admitted to Zhoukou Central Hospital from December 2020 to July 2022 were selected as the research objects,and were divided into control group and study group by random number table method,with 51 cases in each group.The control group received symptomatic treatment and compound glutamine enteric-coated capsules,and the study group received vedolizumab on the basis of the control group.The therapeutic effect was observed in both groups at week 14.The clinical efficacy,intestinal mucosal barrier function,oxidative stress index,and peripheral inflammatory factors were compared between the two groups.Results The total effective rate of the study group was higher than control group(P＜0.05).After treatment,endotoxin,D-lactic acid and diamine oxidase in both groups were lower than before treatment(P＜0.05),and the above indexes in the study group were lower than control group(P＜0.05).Malondialdehyde,lipid peroxide and reactive oxygen species were all lower in both groups after treatment than before treatment(P＜0.05),and the above indexes in the study group were lower than control group after treatment(P＜0.05).The levels of interleukin-4(IL-4),IL-8 and IL-17 in both groups after treatment were lower than before treatment(P＜0.05),and those in the study group after treatment were lower than control group(P＜0.05).Conclusion Vedolizumab combined with compound glutamine enteric-soluble capsules in the treatment of UC can enhance the therapeutic effect,improve the intestinal mucosal barrier function,and inhibit oxidative stress response.
维普
万方数据